Compare Charles River Laboratories Intl. Inc (CRL) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs 8x8 Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while 8x8 Inc trades at $2.2 (market cap $311.98M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 45.6× 8x8 Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and 8x8 Inc for 16 Days on average.
| CRL | EGHT | |
|---|---|---|
Market Cap | $14.23B | $311.98M |
Volume | 1,176,885 | 1,639,086 |
Sector | Health | Technology |
52-Week High | $310.77 | $2.76 |
52-Week Low | $149.93 | $1.59 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $17.06B | $578.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
EGHT trades at $2.14, down 1.38% on the day. The stock exhibits a bullish technical signal with positive moving averages, while recent earnings have consistently beaten expectations. Revenue for 2025 was $715.07M, though the company reported a net loss of $27.21M. Positive news includes a 50% cost reduction for a major client using its platform and recent industry award recognition, highlighting operational strengths.
The outlook is mixed; analyst consensus is a Buy with a $19.77 price target, signaling significant upside potential. However, high debt levels and thin net margins pose risks. The projected return to profitability in 2026 is a key catalyst, but execution risks and competitive pressures in the cloud communications sector remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
